Search

Now showing items 1-10 of 22

Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis

Puentes, F; van der Star, BJ; Victor, M; Kipp, M; Beyer, C; Peferoen-Baert, R; Ummenthum, K; Pryce, G; Gerritsen, W; Huizinga, R;... (2013-09-22)

Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy.

Biela, A; Watkinson, M; Meier, UC; Baker, D; Giovannoni, G; Becer, CR; Krause, S (2015-01-28)

Matrix metalloproteinase-9 (MMP-9) plays an important role in both physiological and pathological processes. This enzyme is a peripheral biomarker of neuroinflammation in multiple sclerosis (MS), a chronic autoimmune disease ...

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

Baker, D; Marta, M; Pryce, G; Giovannoni, G; Schmierer, K (2017-02)

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses

Giovannoni, G; Cutter, G; Pia-Sormani, M; Belachew, S; Hyde, R; Koendgen, H; Knappertz, V; Tomic, D; Leppert, D; Herndon, R;... (2017-02)

How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis

Baker, D; Anandhakrishnan, A; Tuite-Dalton, KA; Lockart-Jones, H; Middleton, RM; Ford, DV; Crowe, C; Giovannoni, G (2016-11)

CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis - Targeting T or B cells?

Agahozo, MC; Peferoen, L; Baker, D; Amor, S (2016-09)

The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

Giovannonin, G; Baker, D; Schmierer, K (2015-01)

Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.

Dubuisson, N; Bauer, A; Buckley, M; Gilbert, R; Paterson, A; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Giovannoni, G;... (2017-10)

BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...

Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.

Baker, D; Giovannoni, G; Schmierer, K (2017-11)

BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...

Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter?

Pryce, G; Baker, D (2018-10)

Since their discovery, the existence of secreted oligoclonal immunoglobulin in the central nervous system in people with multiple sclerosis has been the subject of scientific investigation and debate over several decades. ...